An activation-specific monoclonal antibody (MoAb) termed "Canine Activated Platelet 1" (CAP 1) has been developed and partially characterized. Flow cytometric studies of isolated canine platelets, using adenosine diphosphate (ADP) and platelet activating factor (PAF) as agonists, demonstrated that CAP 1 binding site number was proportional to agonist strength and agonist concentration. MoAb CAP 1 binding was diminished by ethylenediamine-tetraacetic acid, suggesting that the antigen was either stabilized by calcium or antigen binding to the platelet surface was mediated by calcium. ADP-activated gel-filtered platelets also demonstrated reduced binding of MoAb CAP 1 even in the presence of 1 mM CaCI,. Binding of MoAb CAP 1 could be partially restored by activating gel-filtered platelets with PAF, suggesting that the antigen was either present within platelet granule membranes or was exposed after binding of released protein(s) with a platelet receptor. A monoclonal antibody to human platelet glycoprotein IIIa (GPIIIa), which cross-reacts with canine platelet GPIIIa regardless of platelet activation status, did not inhibit binding of MoAb CAP1. MoAb CAPl bound to isolated canine fibrinogen captured on polystyrene microtiter plates in the absence of platelet proteins. Immunoblots indicated that MoAb CAP1 recognizes nonreduced fibrinogen as well as a plasmin digest of isolated canine fibrinogen. Results of the present studies suggest that MoAb CAPl recognizes a receptor-induced binding site on canine fibrinogen.
Platelets are vital to the normal hemostatic process, adhering to exposed subendothelial surfaces3' and providing a framework for coagulation factor assembly and activation. 22 Platelets also contribute to thrombotic processes, particularly when excessive endothelial damage or foreign surfaces are p r e~e n t .~J~ Platelet activation is associated with changes on the platelet surface that can be detected immunologically. 28 Changes associated with platelet activation include reorganization of the glycoprotein IIb-IIIa complex (GPIIb-IIIa) resulting in expression of ligand binding funct i~n ,~~ granule membrane fusion with plasma memb r a n e~,~~ platelet membrane binding of soluble prot e i n~, '~ and expression of binding sites for coagulation proteins involved in the tenase and prothrombinase complexes. 15 Several activation-specific monoclonal antibodies (MoAbs) have been developed for the detection of human platelet activation, and their utility has been well described in a variety of research and clinical appli-~a t i o n s . ' J~J~,~~ Activation-specific MoAbs developed against human platelets have been classified by the surface change they recognize on activated platelets. PAC 1 , 29 which recognizes activated GPIIb-IIIa; MoAb 9F9,33,34 which recognizes binding sites on fibrinogen induced by binding to GPIIb-IIIa (receptor-induced binding site); MoAb LIBS 1 ,13 which recognizes binding sites in GPIIIa induced by binding of ligand (ligand-induced binding site); and MoAb S12,20 which recognizes the alpha granule membrane protein, P-selectin. Unfortunately, few to none of the activation-specific MoAbs crossreact sufficiently with canine platelets to be of value in the evaluation of platelet activation in the dog. Considering that the dog is a primary animal model in the field of cardiovascular research, significant information about platelet activation could potentially be obtained without relying on extensively invasive techniques if appropriate immuno-reagents were available. MD3 and MD6 are rare examples of activation-specific MoAbs developed specifically against canine platelets.IOJ ' These antibodies recognize P-selectin and MoAb MD6 has been of value in evaluating in vivo leukocyte rolling events.
Examples include MoAb
The present study describes the development of an activation-specific MoAb that binds to activated ca-419 Vet Pathol 33:4, 1996 nine platelets. Studies t o date suggest that MoAb CAPl recognizes a receptor-induced binding site on fibrinogen.
Materials and Methods

Monoclonal antibody preparation
The monoclonal antibody (MoAb) was prepared using described methods." Briefly, BALB/c mice were inoculated IP and IV with thrombin-activated, washed canine platelets. IP injections were performed with complete Freund's adjuvant and then repeated 3 weeks later using incomplete Freund's adjuvant. IV injections did not contain adjuvant. Spleen cells from immunized mice were fused with cells from myeloma cell line Ag8X653. Clones were screened by enzyme-linked immunosorbent assay (ELISA) using plates with wells coated with washed canine platelets. Positive clones were recloned by limiting dilution and retested by ELISA. Isotyping of positive clones was performed with a kit (Boehringer Mannheim, Germany).
ELISA-plate preparation and technique for platelets
Platelet-rich plasma (PRP) was isolated from canine blood collected into 3.8% trisodium citrate at a ratio of 9 : 1. Ten microliters of 3 mM PGE, were added to each 10 ml PRP. PRP was washed 3 times with Tangen HEPES buffer (147 mM NaCl, 5 mM KCl, 0.05 mM CaCI,, 0.1 mM MgCI,, 5 mM HEPES, 5.5 mM glucose, pH 7.4) containing 3.0 pM PGE,. The final platelet pellet was resuspended in carbonate buffer (45.3 mM NaHCO,, 18.2 mM Na,CO,, pH 9.6) to yield a final platelet count of lO,OOO/pl. One hundred microliters of platelet suspension was added to each well of 96well microtiter plates and the plates were spun at 416 x g for 10 minutes. Platelets adhering to the plate wells were in the activated state as determined by subsequent ELISA procedures.
Plates to be used immediately were gently blotted upside down on absorbant paper to remove carbonate buffer. Wells were washed gently three times with phosphate-buffered saline (PBStTween 20 (127 mM NaC1, 7.7 mM Na,HPO,, 2.3 mM NaH,PO,, 0.5 ml Tween-20/1,000 ml buffer, pH 7.2) and the wells blotted dry once again. Fifty microliters of each test sample was added to individual wells. Sera collected from immunized mice and control mice were diluted 16 : 1 and used as positive and negative controls, respectively. Plates were incubated at 37 C for 1 hour, supernatants discarded, and wells washed three times with PBS-Tween 20. After blotting dry, 10 pl horseradish peroxidase-conjugated goat anti-mouse IgG (Cappel, Durham, NC) was diluted in 10 ml PBS-Tween 20/plate and 100 p1 added to each well. Plates were incubated at 37 C for 30 minutes and washed three times with PBS-Tween 20. Color development was achieved by addition of ABTS (2-2' azino-D [3-ethyl benzthiazoline sulfonic acid]) and H,O, and incubation of plates for 15 minutes in the dark. Plates were read immediately after incubation.
Plates not used immediately for an ELISA procedure were stored in the refrigerator for up to 8 months. Stored plates were covered and wrapped in plastic to prevent dehydration. Carbonate supernatant was not removed until use.
ELISA -plate preparation and technique for fibrinogen
Canine fibrinogen was isolated from citrated plasma by the method of cold ethanol precipitation9 (and John Davis, personal communication). Comparison of protein concentration by the Coomassie methodS and fibrinogen concentration by the thrombin clotting time method, indicated the isolated fibrinogen was essentially 100% clottable. Fibrinogen was titrated in decreasing concentrations in duplicate on microtiter plates and an ELISA procedure performed using MoAb "Canine Activated Platelet 1" (CAP1) as primary antibody as described above. Binding of MoAb CAPl to canine fibrinogen was compared to binding of MoAb CAPl to albumin, plasma, and serum titrated in duplicate in separate wells.
Gel filtration
Citrated PRP was layered onto a column containing Sepharose 2B equilibrated with Tangen HEPES buffer containing 1 .O mM CaCI, and 0.35% bovine albumin. Platelets were collected in a 4 ml "cloudy" void volume after the clearance of an initial clear void volume of approximately 15 ml.
CAPl effect on platelet aggregation
Platelet aggregation was evaluated in a dual channel platelet aggregometer (Chrono-log Corp., Havertown, PA) equipped with a recorder, as described., PRP (450 pi, 300,000/ p1) was allowed to stir for 1 minute at 37 C prior to addition of 50 p1 ofadenosine diphosphate (ADP), collagen, or platelet activating factor (PAF); or 10 p1 of epinephrine. Final concentrations were 10 and 25 pM for ADP, 20 pM for epinephrine, 0.2 and 1.0 pM for PAF, and 12, 6, and 3 pg/ml for collagen. For experiments evaluating MoAb CAPl effects, antibody in saline buffer, pH 7.4, was added prior to agonist addition. When more than one agent was added to the cuvette, 1 minute of stirring occurred between addition of each agent. Platelets were allowed to stir until maximal platelet aggregation had occurred or for 5 minutes if no reaction occurred. The change in light transmittance was determined using the point of maximal shape change as baseline.
Flow cytometry
Blood was collected from a normal dog into 3.8% trisodium citrate at a ratio of 9 : 1. In selected experiments blood was also collected from a normal human being, a normal horse, and from a dog with Glanzmann's thrombasthenia. PRP was isolated and 10 p1 aliquots added to 100 p1 aliquots of buffer (10 mM HEPES, 145 mM NaC1, 1 mM MgSO,, pH 7.4). To evaluate for binding of antibody to activated platelets, varying concentrations of agonists including ADP and PAF were added to aliquots. In selected experiments, dithiothreitol was added to expose fibrinogen receptors. Agonists were not added to aliquots in which binding of antibody to nonactivated platelets was being determined. Samples with and without added agonists were incubated at room temperature (2 1 C) for 5 minutes, and undiluted hybridoma supernatant containing MoAb CAPl was added to the tubes. After a 20-minute incubation at room temperature, fluorescein isothiocyanate-labeled goat anti-mouse F(ab'), fragments (AMAC, Inc. Westbrook, ME) were added to the tubes and the samples incubated for 20 minutes in the dark. Nonspecific binding of secondary antibody was examined by adding secondary antibody to tubes containing activated and nonactivated platelets without primary antibody. Samples were fixed with 500 pl 2% formalin and immediately evaluated by flow cytometry (Coulter Epics Elite, Hialeah, FL).
In selected experiments, MoAb CAP 1 binding to activated gel-filtered platelets in the presence of 1 mM calcium and 0.35% albumin was evaluated before and after the addition of varying concentrations of purified canine fibrinogen. Additional selected experiments entailed incubation of 25 p1 plasmin (1 Unit/ml) with 100 p1 canine fibrinogen (1 65 mg/ dl) in the presence of 5 mM CaCl, at 37 C for 1 hour. Fifty microliters of the above mixture was then incubated with MoAb CAPl at 21 C for 30 minutes. Binding of CAPl to activated and nonactivated platelets was evaluated after a 30-minute incubation with the above latter mixture as well as after a 30-minute incubation with PBS, PBS + plasmin, and canine fibrinogen.
The fluorescent signal-to-noise ratio (FSN) in test samples was calculated using a computer program (Matt Birkner, Aubum, AL), subtracting nonspecific fluorescence obtained in control samples and converting values to linear numbers. The formula is below:
Calculation of the FSN allowed direct comparison of binding site number between samples within an e~p e r i m e n t .~~.~'
Imrnunoblotting
Blood was collected into ethylenediamine-tetraacetic acid from a normal dog, a human being, and a dog with Glanzmann's thrombasthenia. PRP was isolated and washed three times after the addition of PGE, (3.0 pM final). Prior to the final wash, the sample was halved to obtain two pellets. The nonreduced platelet pellet was resuspended in 1% sodium dodecyl sulfate (SDS), 0.06 M Tris, 25% glycerol, pH 6.8, at a count of 5 million/pl. The reduced platelet pellet was resuspended similarly except that the SDS solution also contained 5% mercaptoethanol. All samples were boiled for 5 minutes and centrifuged at 10,000 x g for 5 minutes. Supernatants were dispersed into aliquots and frozen at -80 C until use.
One hundred micrograms of platelet protein in 50-p1 aliquots was loaded per lane of a 5-1 5% gradiant gel. Reduced and nonreduced samples were evaluated in different experiments. Samples were thawed, boiled, and centrifuged just prior to loading. After electrophoresis, separated platelet proteins and molecular weight standards were either stained with Coomassie blue or transferred to polyvinylidene difluoride membranes (PVDF Millipore, Corp, Bedford, MA) using an electroblotting apparatus. PVDF membranes were blocked with casein and incubated with undiluted hybridoma supernatant containing MoAb CAPl overnight in the cold. In control experiments, PVDF membranes were incubated with hybridoma cell culture media not containing antibody. Membranes were washed repeatedly with PBS. Alkaline phospha-L o g Fluorescence Fig. 1 . Flow cytometric analysis of monoclonal antibody (MoAb) "Canine Activated Platelet 1 " (CAP1) binding to canine platelets. Fig. 1 A, B : Fluorescence intensity observed with isotype control antibody or MoAb CAPl in the presence of nonactivated canine platelets. Fig. 1C : Fluorescence intensity observed when MoAb CAPl was added to platelet activating factor-activated canine platelets.
tase-conjugated goat affinity-purified F(ab'), fragments to mouse IgG (Cappel, Durham, NC) were added and incubated for a minimum of 90 minutes. Color development was achieved using a kit (Bio-Rad, Hercules, CA).
Commercially available primary antibodies against human platelet glycoprotein (GP) GPIb and GPIIIa (DAKO Corp., Carpinteria, CA) and against human platelet GPIIb (AMAC, Inc.) also were evaluated.
In additional experiments, canine fibrinogen and plasmindigested canine fibrinogen (5 mM CaCI,, reduced and nonreduced), were electrophoresed ( 5 5 pg total protein) and transferred to PVDF membranes. MoAb CAP 1 binding was evaluated as described above.
Results
Generation of monoclonal antibody (MoAb)
Approximately 500 hybridoma cultures were generated from fusion experiments that utilized splenocytes from mice immunized with thrombin-activated, washed, canine platelets. The screening of hybridoma culture supernatants by enzyme-linked immunosorbent assay (ELISA) identified approximately five that reacted with activated canine platelets. Of those five, only two were successfully recloned by limiting dilution and retested by ELISA. Isotyping determined one of these antibodies to be a n IgG, kappa. This antibody was designated "Canine Activated Platelet 1" (CAP 1).
Flow cytornetric analysis
Physiologic agonists. MoAb C A P l did not bind to nonactivated canine platelets in citrated platelet-rich plasma (PRP) but did bind to platelets activated with adenosine diphosphate (ADP) or platelet activating factor (PAF) (Fig. 1 ). The amount of binding of MoAb CAP 1 was dependent on agonist concentration as well as on agonist type ( Table 1 ). As the concentration of Table 1 . Monoclonal antibody "Canine Activated Platelet 1" binding to resting and activated canine platelets in terms of fluorescent signal-to-noise ratio (FSN). ADP increased, the fluorescent signal-to-noise ratio (FSN) also increased. A higher FSN was obtained in response to 0.2 pM PAF than to 100 pM ADP. Epinephrine alone did not induce MoAb CAPl binding to canine platelets; however, 20 pM epinephrine in combination with 10 pM ADP induced a similar number of CAPl binding sites to that obtained with 100 pM ADP. Binding of MoAb CAPl to activated platelets in PRP isolated from blood collected into ethylenediamine-tetraacetic acid (EDTA) (0. l 5% final) was markedly reduced compared to citrated samples ( Table  2) . Similar results were obtained if EDTA was added to citrated PRP prior to or within 5 minutes of agonist addition. EDTA added after agonist and MoAb CAP 1 but prior to secondary antibody had no effect on MoAb CAPl binding (data not shown). Activated gel-filtered platelets (GFP) suspended in buffer containing 1 mM CaC1, did not bind MoAb CAP 1 as readily as platelets Table 2 . Effect ofethylenediamine tetraacetic acid (EDTA) on binding of monoclonal antibody "Canine Activated Platelet 1" to resting and activated canine platelets. suspended in citrated plasma. PAF was better than ADP in inducing exposure of binding sites for CAPl in GFP ( Table 3) . Addition of purified canine fibrinogen to GFP restored MoAb CAPl binding to activated platelets in a concentration-dependent manner. Incubation of MoAb CAP I with plasmin-digested canine fibrinogen resulted in a 70% reduction in binding of CAP 1 to activated platelets. Incubation of MoAb CAPl with intact canine fibrinogen resulted in a 27% decrease in binding of CAP 1 to activated platelets. Incubation of MoAb CAPl with plasmin or phosphate-buffered saline alone did not affect CAPl binding ( Table 4 ).
Monoclonal antibody CAP 1 binding to human platelets could not be detected by flow cytometric techniques regardless of platelet activation status. Conversely, MoAb CAPl did bind to equine platelets in an activation-specific manner (data not shown).
A commercially available monoclonal antibody against human platelet glycoprotein (GP) GPIIIa ( Y 2 / 5 1, DAKO) was demonstrated to have strong cross-reactivity with normal canine platelet GPIIIa ( Table 5) . MoAb Y2/51 bound to GPIIIa regardless of platelet activation status. MoAb CAPl added to activated canine platelets prior to the addition of fluorescein isothiocyanate (F1TC)-labeled Y2/5 1 did not inhibit binding of Y 2 / 5 1. In control experiments, nonlabeled Y 2 / 5 1 did inhibit binding of FITC-labeled Y 2 / 5 1.
MoAb SZ22 (AMAC) and MoAb AN51 (DAKO) against human platelet GPIIb and GPIb, respectively, Competitive inhibition and species variations. Platelets from a dog with Glanzrnann's thrornbasthenia. MoAb CAPl did not bind to platelets from a dog with Glanzmann's thrombasthenia (GT) regardless of type or concentration of agonist present. MoAb Y2/5 1 bound slightly to GT platelets; binding was not affected by agonist addition. DTT did not expose binding sites for MoAb CAPl on GT platelets suspended in citrated plasma (data not shown).
Fibrinogen binding. MoAb CAPl bound to fibrinogen captured on polystyrene plates; binding diminished as the concentration of fibrinogen diminished. MoAb CAP 1 did not bind to albumin or serum titrated on polystyrene plates, but it did bind to citrated plasma.
Platelet aggregation
MoAb CAPl (5.5 pg final) inhibited 25 and 10 pM ADP-induced platelet aggregation; the inhibition was not as evident when the ADP response was potentiated with 20 pM epinephrine ( Table 7) . Inhibition of ADPinduced platelet aggregation was manifested as a de- well as by induction of a reversible aggregation response. MoAb CAP 1 also inhibited collagen-induced platelet aggregation responses; the inhibition was more evident at lower agonist concentrations and was manifested by a reversible response when platelets were activated with 3 pglml collagen. MoAb CAP 1 inhibited the extent of 0.2 pM PAF-induced platelet aggregation and also induced a reversible response. MoAb CAPl did not inhibit 1 . O pM PAF-induced platelet aggregation.
Immunoblotting
MoAb CAPl bound to immunoblot preparations of washed normal canine platelets at a broad protein band Table 6 . Comparison of binding of monoclonal antibody "Canine Activated Platelet 1" to dithiothreitol-incubated resting canine platelets in platelet-rich plasma (PRP) with and without added ethylenediamine tetraacetic acid, to dithiothreitol-incubated washed canine platelets in buffer containing 1 mM calcium, and to PAF*-activated platelets. spanning 90 to 100 kd and also at a band of approximately 340 kd. Bands did not appear in control experiments where primary antibody was eliminated from cell culture media (data not shown). CAP 1 did not bind to reduced preparations of canine fibrinogen but did bind to nonreduced preparations at a band of approximately 340 kd. MoAb CAPl bound to nonreduced, plasmin-digested, canine fibrinogen at bands of approximately 105 and 180 kd (Fig. 2) . Reduction of plasmin-digested fibrinogen samples eliminated MoAb CAPl binding. MoAb CAPl bound minimally to reduced or nonreduced normal human platelets, displaying a faint thin band at approximately 95 kd. MoAb Y2/5 1 bound to a protein band of approximately 100 kd in the normal dog platelet sample and to a band of 95 to 105 kd in the human platelet sample. MoAb Y2/ 5 1 did not bind to canine GT platelets.
Discussion
Glycoprotein (GP) complex IIb-IIIa, also known as the fibrinogen receptor and designated with the integrin classification of aIIbP3, is the principal glycoprotein complex involved in platelet a~t i v a t i o n .~~
The ligand binding function of the complex is not expressed on the surface of nonactivated platelets.8 Physiologic agonists capable of activating platelets, and inducing the ligand binding function of GPIIb-IIIa, include adenosine diphosphate (ADP), collagen, thrombin, and platelet activating factor (PAF). Epineprine, a poten-tiator of canine platelet activation,18,21 can enhance the number of binding sites induced by weaker agonists such as ADP. The principal ligand bound by GPIIb-IIIa is fibrinogen; however, other proteins capable of binding to the complex include von Willebrand factor, vitronectin, and f i b r~n e c t i n .~~ Binding of ligand to the receptor has been demonstrated to be divalent cationdependent; calcium is believed to be of most importance not only for ligand binding, but also for stability of the GPIIb-IIIa complex.6
Binding of ligand to the fibrinogen receptor induces alterations in the conformation of the complex, as well as in the ligand, that can be detected immunological-IY.~' Monoclonal antibodies that recognize neoantigens on receptors as a result of ligand binding are designated as ligand-induced binding site (LIBS) antibodies. To date, LIBS antibodies have been described for human platelet GPIIb and GPIIIa. Neoantigens expressed on the ligand as a result of binding to a receptor are termed receptor-induced binding sites (RIBS). RIBS antibodies have been developed against human fibrino-In the present study, monoclonal antibody (MoAb) "Canine Activated Platelet 1 " (CAP 1) specifically recognized an epitope on activated canine platelets. MoAb CAPl did not bind to nonactivated platelets. When blood was collected into ethylenediamine-tetraacetic acid (EDTA) instead of citrate, MoAb CAPl binding was markedly reduced. This may have indicated that gen. 1, 33, 34 binding of MoAb CAP 1 was calcium-dependent or that the antigen recognized by MoAb CAP 1 either was stabilized by calcium or was dependent on calcium for binding to the platelet surface. When platelets were collected in citrate and EDTA was added just prior to, or 5 minutes after, agonist addition, MoAb CAPl binding was completely inhibited. EDTA added after agonist and after MoAb CAPl but prior to secondary antibody did not interfere with MoAb CAPl binding.
MoAb CAP 1 binding was reduced when gel-filtered platelets (GFP) containing sufficient calcium were activated, suggesting that the CAP 1 antigen was present primarily within plasma. The reduction in number of binding sites was most extreme when ADP was used as an agonist. The finding that PAF was better able to induce MoAb CAPl binding sites in GFP than ADP, suggested that the antigen recognized by MoAb CAPl was also present within platelet granules and could be released upon platelet activation by a strong agonist. The calcium-dependent nature of MoAb CAPl recognition supported the theory that MoAb CAP 1 bound to an antigen that required calcium for binding to a platelet receptor. Canine platelets, in contrast to human platelets, release minimal to no detectable dense granule contents in response to ADP as determined using J4C-~er~tonin.4 Although not measured directly, these experiments suggested that ADP also does not induce significant canine platelet alpha granule release.
Dithiothreitol (DTT) has been shown to induce human platelet aggregation by reducing disulfide bonds in the platelet integrin aIlbP3 .17, 35 DTT-induced platelet aggregation is calcium-and fibrinogen-dependent. In this study, DTT was able to induce exposure of CAPl binding sites in normal canine platelets suspended in citrated plasma. DTT was not able to induce CAPl binding sites in the presence of EDTA or in washed platelet suspensions containing 1 .O mM CaC1,. These studies further supported that antigen expression was related to binding of protein, likely fibrinogen, to the platelet surface. DTT also was unable to induce CAPl binding sites on canine Glanzmann's thrombasthenia (GT) platelets. DTT has been found to induce fibrinogen binding sites on the platelets of Strasbourg I variant GT in human beings.I7 In this Type I1 variant, an Arg-214 +. Trp mutation is present on the p3 subunit.
The inability of MoAb CAPl to interfere with the binding of MoAb Y 2 / 5 1, a monoclonal antibody against GPIIIa, suggested either that MoAb CAPl did not recognize GPIIIa or recognized an epitope on GPIIIa that did not sterically hinder the binding of MoAb Y2/ 5 1. In support of the CAP 1 antigen being a part of GPIIIa, was the finding by immunoblot that MoAb CAPl recognized a protein very similar in migration pattern to GPIIIa. In defiance of the CAPl antigen simply being activated GPIIIa was the inability of These experiments alone suggested that MoAb CAP 1 recognized either a RIBS or LIBS on activated canine platelets. The finding that MoAb CAPl bound to isolated fibrinogen captured on polystyrene wells suggested that MoAb CAPl recognized a RIBS on fibrinogen. The epitope recognized by MoAb CAPl may have been exposed as a result of binding of fibrinogen to microtiter wells; a similar phenomenon was reported for RIBS MoAb 9F9.I These investigators also demonstrated that the RIBS-I epitope on human fi-Vet Pathol 33:4, 1996 brinogen resides within the gamma chain segment of the D domain. Plasmin digests of human fibrinogen in the presence of 5 mM CaC1, yielded a band of approximately 100 kd that reacted with an anti-human fibrinogen RIBS antibody.34 MoAb CAP 1 recognized a plasmin-digested fibrinogen band of approximately 105 kd. Incubation of MoAb CAPl with plasmin-digested canine fibrinogen reduced the binding of CAP 1 to activated platelets by 70%, suggesting that the majority of MoAb CAP 1 was "adsorbed" by antigen prior to use in flow experiments. Although MoAb CAPl also recognizes intact fibrinogen, as demonstrated by immunoblot techniques, fibrinogen incubation with CAP 1 only reduced binding to activated platelets by 27%. The recognition of MoAb CAPl predominantly for bound fibrinogen enabled the use of platelet-rich plasma in flow cytometric experiments.
The finding that MoAb CAPl inhibited not only the extent of platelet aggregation but also induced a reversible aggregation response suggests that RIBS epitopes on fibrinogen may play a role in the development of the platelet aggregation response, as proposed in 1991 by Zamarron et al. 34 The finding also raises the possibility of using antibodies against RIBS epitopes on fibrinogen in vivo to inhibit or reduce platelet responses. Because the antibodies are specific for bound fibrinogen, the antibodies would only bind at sites of platelet activation.
Another potential use for RIBS antibodies such as MoAb CAPl is for the detection of in vivo platelet activation in the dog. Considering the importance of the dog in cardiovascular research, and the limited availability of immunoreagents that cross-react with canine platelets, these types of antibodies may glean useful information early in the course of investigation without relying on more invasive techniques.
Still another important role for activation-specific monoclonal antibodies is for the characterization of platelet function defects. The detection and characterization of platelet function defects in animals often leads to a better understanding of platelet biology and physiology in general. To date, most of the monoclonal antibodies that detect platelet activation-specific events have limited species cross-reactivity. This finding in itself is interesting; however, with limited access to appropriate immunoreagents, investigators studying nonhuman platelet activation are at a distinct disadvantage.
